Compliance and persistence with Alzheimer’s disease treatment: a retrospective analysis of multiregional hospital databases in Thailand

References

• United Nations, Department of Economic and Social Affairs, Population Division. World population ageing. New York: United Nations; 2015
   Google Scholar
• Prince M, Wimo A, Guerchet M, et al. World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International (ADI); 2015
   Google Scholar
• Prince M, Jackson J. World Alzheimer report. London, UK: Alzheimer’s Disease International; 2009
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Association; 2013
   Google Scholar
• Wong CW. Pharmacotherapy for dementia: a practical approach to the use of cholinesterase inhibitors and memantine. Drugs Aging 2016;33:451-60
   PubMed Web of Science ®Google Scholar
• DiPiro J, Talbert R, Yee G, et al. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill Education; 2015
   Google Scholar
• Tricco AC, Ashoor HM, Soobiah C, et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc 2018;66:170-8
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Johannsen P. Long-term cholinesterase inhibitor treatment of Alzheimer’s disease. CNS Drugs 2004;18:757-68
   PubMed Web of Science ®Google Scholar
• Ku LE, Li CY, Sun Y. Can persistence with cholinesterase inhibitor treatment lower mortality and health-care costs among patients with Alzheimer’s disease? A population-based study in Taiwan. Am J Alzheimers Dis Other Dementias 2018;33:86-92
   PubMed Web of Science ®Google Scholar
• El-Saifi N, Moyle W, Jones C, et al. Medication adherence in older patients with dementia: a systematic literature review. J Pharm Pract 2017:897190017710524
   Web of Science ®Google Scholar
• Lam WY, Fresco P. Medication adherence measures: an overview. BioMed Res Int 2015;2015:217047
   PubMed Web of Science ®Google Scholar
• Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Managed Care 2001;10:42-5
   Google Scholar
• Aekplakorn W. The fifth national health survey of Thai population by medical examination. Nonthaburi: Health Systems Research Institute (HSRI); 2014
   Google Scholar
• Official Statistics Registration Systems. National population by age. Bangkok, Thailand: OSRS; 2015. Available at: http://stat.dopa.go.th/stat/statnew/upstat_age.php [Last accessed 23 December 2016]
   Google Scholar
• Prasat Neurological Institute. Clinical practice guideline: dementia. Bangkok: Prasat Neurological Institute; 2014
   Google Scholar
• Asia Pacific Observatory on Health Systems and Policies. Policy note: Thailand health systems in transition. Geneva, Switzerland: World Health Organization (WHO); 2016
   Google Scholar
• Eddy D. Health technology assessment and evidence-based medicine: what are we talking about? Value Health 2009;12(Suppl 2):S6-S7
   PubMedGoogle Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• World Health Organization. International statistical classification of diseases and related health problems 10th revision (ICD-10). WHO; 2016. Available at: http://apps.who.int/classifications/icd10/browse/2016/en [Last accessed 6 February 2018]
   Google Scholar
• Dilokthornsakul P, Chaiyakunapruk N, Nimpitakpong P, et al. The effects of medication supply on hospitalizations and health-care costs in patients with chronic heart failure. Value Health 2012;15(1 Suppl):S9-S14
   PubMed Web of Science ®Google Scholar
• Herrmann N, Binder C, Dalziel W, et al. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging 2009;26:403-7
   PubMed Web of Science ®Google Scholar
• Le Couteur DG, Robinson M, Leverton A, et al. Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Aust J Ageing 2012;31:164-9
   Web of Science ®Google Scholar
• Ahn SH, Choi NK, Kim YJ, et al. Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea. Arch Pharm Res 2015;38:1255-62
   PubMed Web of Science ®Google Scholar
• Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003;19:707-14
   PubMed Web of Science ®Google Scholar
• Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010;1:274-8
   PubMedGoogle Scholar
• Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. 3rd ed. College Station, TX: StataCorp LP; 2012
   Google Scholar
• Massoud F. Persistence with cholinesterase inhibitor treatment in Alzheimer’s disease. Can J Neurol Sci 2013;40:623-4
   PubMed Web of Science ®Google Scholar
• Brewer L, Bennett K, McGreevy C, et al. A population-based study of dosing and persistence with anti-dementia medications. Eur J Clin Pharmacol 2013;69:1467-75
   PubMed Web of Science ®Google Scholar
• Riffenburgh RH. Statistics in medicine 2nd ed. Boston, US: Elsevier Academic Press; 2006
   Google Scholar
• Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-33
   PubMed Web of Science ®Google Scholar
• Mucha L, Shaohung S, Cuffel B, et al. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer’s disease. J Manag Care Pharm 2008;14:451-61
   PubMed Web of Science ®Google Scholar
• Blais L, Kettani FZ, Perreault S, et al. Adherence to cholinesterase inhibitors in patients with Alzheimer’s disease. J Am Geriatr Soc 2009;57:366-8
   PubMed Web of Science ®Google Scholar
• Poon I, Lal LS, Ford ME, et al. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann Pharmacother 2009;43:185-93
   PubMed Web of Science ®Google Scholar
• Haider B, Schmidt R, Schweiger C, et al. Medication adherence in patients with dementia: an Austrian cohort study. Alzheimer Dis Assoc Disord 2014;28:128-33
   PubMed Web of Science ®Google Scholar
• Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer’s disease patients receiving oral therapy. Curr Med Res Opin 2010;26:1957-65
   PubMed Web of Science ®Google Scholar
• Dybicz SB, Keohane DJ, Erwin WG, et al. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother 2006;4:154-60
   PubMedGoogle Scholar
• Kroger E, van Marum R, Souverein P, et al. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging 2010;27:663-75
   PubMed Web of Science ®Google Scholar
• Pariente A, Fourrier-Reglat A, Bazin F, et al. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology 2012;78:957-63
   PubMedGoogle Scholar
• Bent-Ennakhil N, Coste F, Xie L, et al. A Real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients. Neurol Ther 2017;6:131-44
   PubMed Web of Science ®Google Scholar
• Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer’s disease. Pharmacoepidemiol drug Safety 2010;19:670-9
   PubMed Web of Science ®Google Scholar
• Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer’s disease. Drugs Aging 2005;22:695-707
   PubMed Web of Science ®Google Scholar
• Bohlken J, Jacob L, Kostev K. Association between anti-dementia treatment persistence and daily dosage of the first prescription: a retrospective analysis in neuropsychiatric practices in Germany. J Alzheimer’s Dis 2017;58:37-44
   PubMed Web of Science ®Google Scholar
• World Health Organization. mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings. Geneva, Switzerland: WHO Press, World Health Organization; 2010
   Google Scholar
• Conn VS, Ruppar TM. Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis. Prevent Med 2017;99:269-76
   PubMed Web of Science ®Google Scholar
• Saleh S, Kirk A, Morgan DG, et al. Less education predicts anticholinesterase discontinuation in dementia patients. Can J Neurol Sci 2013;40:684-90
   PubMed Web of Science ®Google Scholar
• Tian H, Abouzaid S, Chen W, et al. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study. Alzheimer Dis Assoc Disord 2013;27:182-6
   PubMed Web of Science ®Google Scholar
• Maxwell CJ, Stock K, Seitz D, et al. Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors. Can J Psychiatry 2014;59:624-31
   PubMed Web of Science ®Google Scholar
• Lai EC, Man KK, Chaiyakunapruk N, et al. Brief report: databases in the Asia-Pacific region: the potential for a distributed network approach. Epidemiology 2015;26:815-20
   PubMed Web of Science ®Google Scholar